Meeting
2019 Genitourinary Cancers Symposium
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
Authors
Alastair Thomson
Royal Cornwall Hospital, Truro, United Kingdom
Alastair Thomson , Adam Pollard , Frances May Mark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 298)
DOI
10.1200/JCO.2019.37.7_suppl.298
Abstract #
298
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2020 Genitourinary Cancers Symposium
Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.
First Author: Andrew Lachlan Schmidt
Poster
2014 Genitourinary Cancers Symposium
Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer (mCRPC): Results from an expanded access program.
First Author: David Thomson